



Companies in Paris life science park Biocitech raise EUR 90 million in 12 months

Achievements in the year to September include 20 patents, more than 25 partnerships between resident companies, two clinical trials, nine major scientific advances and 25 publications in peer-review journals

Biocitech comes top of the class in France and joins leading pack in Europe

Paris, September 21st 2007—Biocitech, the Paris life science technology park, announces today that the companies it hosts raised EUR 89.8 million in the 12 months to September. This is more than any other single French site in the same period, and marks Biocitech out as one of the leading technology parks in Europe.

The funding raised at Biocitech represents about one-third of the total funds raised by French biotechnology companies in the last 12 months. On top of this, Biocitech companies garnered nearly EUR 4 million of state aid through the OSEO-INNOVATION and Medicen schemes.

Biocitech continued to set the pace for collaborations between resident companies with 25 new agreements intra-muros, and another 30 with outside institutions or companies. Some four in-licensing and eight out-licensing deals have been announced.

Biocitech companies have also forged ahead in the scientific area during this time: five proofs-of-concept, 20 patents filed or granted, one pre-clinical trial, two Phase I trials started, and nine other significant scientific advances made. They have achieved more than 25 publications in peer-review journals.

"We can only admire and congratulate the companies at Biocitech for what they have achieved in business, science, technology and finance fields," said Jacques Lhomel, Biocitech director. "The impressive number of partnerships between our residents provides backing for our policy of encouraging them to use the synergies that exist between them and to increase the "campus-effect" we have here.

"We have moreover welcomed three new companies to Biocitech since last June and organized ten on-site business or scientific conferences. We will continue to organize similar events to attract new companies and meet the development needs of companies already here."

About Biocitech

The Biocitech technology park for life sciences offers a world-class environment and services for the development of biotechnology, biopharmaceutical and fine chemical companies.

Biocitech is on the outskirts of Paris, only 20 minutes from the city center and from Charles de Gaulle airport. It is privately-owned and provides secure premises and comprehensive facilities based on the latest technology. It has received regulatory approval for conformity to environmental protection standards. Companies can use one or many of the services offered. These include offices, laboratories and a range of technical and scientific services, - all designed to let entrepreneurs concentrate their time and resources on their core business.

Companies already established at Biocitech represent a wide variety of complementary disciplines and many are working on collaborative projects.

Along with other organizations in the Ile-de-France region around Paris, Biocitech plays a key role in the Medicen Paris Region network. This is a healthcare and new therapy cluster designated by the French government as internationally competitive and hence qualified for special privileges.

For further information: <http://www.biocitech.com>